Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.75 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.49 |
| ▸ | SCN1A | P35498 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.45 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2411147 | 0.89 | SCN10A (0.79) | SCN10ASCN5ASCN9ASCN2ASCN3A | |
| SCHEMBL263118 | 0.86 | SCN10A (1.00) | SCN10ASCN5ASCN9ASCN1ASCN2A | |
| SCHEMBL2413724 | 0.85 | SCN10A (0.72) | SCN10ASCN5ASCN9ASCN2ASCN3A | |
| SCHEMBL2415948 | 0.84 | SCN10A (0.54) | SCN10ASCN5ASCN9ASCN1ACHRNA7 | |
| SCHEMBL2420059 | 0.84 | SCN10A (0.54) | SCN10ASCN5ASCN9ASCN1ACHRNA7 | |
| SCHEMBL2418091 | 0.84 | SCN10A (0.53) | SCN10ASCN5ASCN9ASCN1ACHRNA7 | |
| SCHEMBL2418806 | 0.84 | SCN10A (0.53) | SCN10ASCN5ASCN9ASCN1ANPC1 | |
| SCHEMBL2410050 | 0.83 | SCN10A (0.52) | SCN10ASCN5ASCN9ASCN1ACHRNA7 | |
| SCHEMBL2413029 | 0.82 | SCN10A (0.80) | SCN10ASCN5ASCN9ASCN2ASCN3A | |
| SCHEMBL2416115 | 0.81 | SCN10A (0.76) | SCN10ASCN5ASCN9ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945630-B1 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2011-09-21 | — | — | EP | claimed |
| US-7572797-B2 | Amino substituted pyrazine derivatives for the treatment of pain | PFIZER INC. (US) | 2009-08-11 | — | — | US | claimed |
| EP-1945630-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2008-07-23 | — | — | EP | claimed |
| WO-2007052123-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | claimed |
| US-20070105872-A1 | N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide | PFIZER LIMITED | 2007-05-10 | — | — | US | claimed |
| EP-1945630-B1 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2011-09-21 | — | — | EP | disclosed |
| US-7572797-B2 | Amino substituted pyrazine derivatives for the treatment of pain | PFIZER INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1945630-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007052123-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | disclosed |
| US-20070105872-A1 | N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105872-A1 | N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide | P2RX5, P2RX3, AADAC | SCN10A 245/4885SCN5A 13/4885SCN9A 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.